Phase 4 N=45 Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)
ADHD NOS
Primary: ADHD-Clinical Global Impression — 29 subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=34 Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS
ADHD
Primary: DSM-IV ADHD Rating Scale (AISRS) Score Change — -17.5; -10.6; -6.9 Units on a scale
Phase 2 N=20 Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Total AISRS Score at the End of Double-blind Treatment (Week 8) — -17; -17 units on a scale
Phase 3 N=52 Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening
Attention Deficit-Hyperactivity
Primary: Adult ADHD Investigator Symptom Rating Scale (AISRS) Score at End of Placebo Lead-In — 37.2 score on a scale
Phase 3 N=303 Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)
ADHD · Substance Abuse
Primary: ADHD Severity — -20.6; -21.8 units on a scale
Phase 2 N=341 Adult Attention Deficit Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline at Week 4 in ADHD Symptoms Measured With the ADHD Rating Scale Version IV With Adult Prompts (ADHD RS IV) — -12.38; -13.88; -9.7 units on a scale…
N/A N=70 Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder
Attention Deficit Hyperactivity Disorder · Substance Abuse
Primary: Change in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Attention-deficit/Hyperactivity Disorder (ADHD) Checklist — 18.61; 18.19 units on a…
N/A N=29 Neuroimaging of Diet in ADHD: Phase I
Attention Deficit Disorder With Hyperactivity
Primary: ADHD Rating Scale IV — 18.0; 21.3 units on a scale
Phase 3 N=86 NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Swanson, Kotin, Agler, M-Flynn, and Pelham Rating Scale (SKAMP)-Combined Scores-Average of All Post-Dose Time-Points — 19.1; 12.1 units on a scale — p=<0.001
Phase 3 N=87 NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Score — 24.3; 17.3 score on a scale — p=<0.0001
Phase 4 N=171 Attention Deficit Disorder Medication Response Study
ADHD - Inattentive Type · ADHD - Combined Type
Primary: Attention Deficit Hyperactivity Disorder Total Symptom Score — 21.4; 30.0; 20.2; 29.7 units on a scale — p=<0.05
Phase 4 N=71 Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials
Attention Deficit Hyperactivity Disorder
Primary: Adult ADHD Investigator Symptom Rating Scale (AISRS) — 37.0; 15.0 units on a scale
Phase 3 N=60 Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
Autism
Primary: ADHD Rating Scale (ADHDRS)-Home Version Total Score (Randomized Phase) — 28.7; 34.0 units on a scale
N/A N=78 Nicotine and Behavior in Adult ADHD
ADHD
Primary: ADHD Symptoms — 71.2; 78.4; 47.4; 55.5 Percent of item endorsement — p=<0.025
Phase 4 N=96 Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Attention Deficit / Hyperactivity Disorder Total Sum Score of All 18 ADHD Symptom Items — 26.54; 25; 18.94; 18.46 Score
N/A N=18 Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Attention Deficit Hyperactivity Disorder
Primary: Change in Adult ADHD Investigator Symptom Rating Scale Score — 17.3 units on a scale
Phase 4 N=27 Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance?
ADHD
Primary: Dyadic Parent-Child Interaction Coding System (DPICS) - Behavior Counts — 67.2; 42.1; 53.8; 40.1 behaviors
Phase 3 N=320 Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Severity of Attention Deficit Hyperactivity (ADHD) Symptoms — -11.1; -18.2; -18.1 score on a scale
Phase 3 N=24 Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
Autism · Attention Deficit Disorder With Hyperactivity
Primary: Mean Conners' Teacher ADHD Index T Score by Dose — 72.8; 63.1; 63.6; 61.5 Units on a scale (T-scores) — p==.001
Phase 4 N=3 An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.
Attention Deficit Hyperactivity Disorder
Primary: Change in Adult Investigator Symptom Rating Scale (AISRS) Scores From Baseline — -5 Units on a scale
Phase 3 N=255 Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
ADHD · Smoking
Primary: Prolonged Abstinence — 25; 28 participants
N/A N=26 Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study
Attention Deficit Hyperactivity Disorder (ADHD) · Executive Function Deficits (EFD)
Primary: Percent Change in Global Executive Composite T-Score on the Behavior Rating Inventory of Executive Function-Adult (BRIEF-A) — -24; -21 percentage change from baseline…
N/A N=32 Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study
Attention Deficit Hyperactivity Disorder · Nicotine Dependence
Primary: The Number of Subjects in Each Treatment Group Exhibiting Sustained, 4-week Smoking Abstinence, Defined as CO Levels <= 4 Ppm for Each Post-quit Study Visit. — 5; 3…
Phase 3 N=217 SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
ADHD
Primary: Change From Baseline in the Oppositional Subscale of the Conners' Parent Rating Scale-Revised Long Form (CPRS-R:L) Score at Up to 8 Weeks — -10.8; -7.0 Units on a scale…
N/A N=88 Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults
Attention Deficit Disorder With Hyperactivity
Primary: Inattention Subscale — -13.71; -16.18 units on a scale
N/A N=39 Pilot Feasibility Study of Neurofeedback for Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Feasibility of Double-blind, Sham-controlled Design #1. Recruitment Number — 26; 13 participants
N/A N=84 Using Computers to Assist in the Diagnosis and Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Number of Children Diagnosed With ADHD With Structured Diagnostic Assessment — 34; 16 number of kids
Phase 4 N=97 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder
Autistic Disorder · Attention Deficit Disorder With Hyperactivity
Primary: ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score — 40.7; 38.6; 32.3; 37.3 units on a scale — p=<0.001
Phase 2 N=740 Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder
Primary: Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase B — -9.02; -9.71 score on a scale — p=0.5845
Phase 3 N=349 An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder · Attention Deficit Disorders With Hyperactivity · Attention Deficit Hyperactivity Disorders
Primary: Change in ADHD-RS-IV Total Score From Baseline at Up to One Year — -24.8 Units on a scale — p=< 0.0001